Dr. Rohit Kumar, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 14
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 284
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
KY license 51209 -
Hospice and Palliative Medicine (Internal Medicine) Physician
AR license NA -
Internal Medicine Physician
IL license 125065724
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Norton Hospitals, Inc Louisville, KY
- Uofl Health - Jewish Hospital and Mary & Elizabeth Hospital Louisville, KY
- Baptist Health Hardin Elizabethtown, KY
- University of Louisville Hospital Louisville, KY
Medical groups
- University of Louisville Physicians Inc (1,445 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 284
- Services billed
- 1,025
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 303 | 114 |
| Established patient office or other outpatient visit, 40-54 minutes | 188 | 65 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 144 | 57 |
| New patient office or other outpatient visit, 60-74 minutes | 60 | 60 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 43 | 42 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 33 | 32 |
| Established patient office or other outpatient visit, 20-29 minutes | 32 | 26 |
| New patient office or other outpatient visit, 45-59 minutes | 30 | 30 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 27 | 24 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Abiraterone Acetate | 180 |
| Prednisone Other prescribers in Louisville, KY | 155 |
| Oxycodone Hcl Other prescribers in Louisville, KY | 114 |
| Xtandi (enzalutamide) | 96 |
| Cabometyx (cabozantinib s-malate) | 59 |
| Potassium Chloride Other prescribers in Louisville, KY | 54 |
| Dexamethasone Other prescribers in Louisville, KY | 50 |
| Prochlorperazine Maleate Other prescribers in Louisville, KY | 38 |
| Orgovyx (relugolix) | 36 |
| Nubeqa (darolutamide) | 35 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 30 companies reported 125 payments worth $13,987 in total to this clinician.
| Pfizer Inc. | $4,290 |
|---|---|
| EMD Serono, Inc. | $2,862 |
| Springworks Therapeutics, Inc. | $2,253 |
| AstraZeneca Pharmaceuticals LP | $1,472 |
| Deciphera Pharmaceuticals Inc. | $1,110 |
| Daiichi Sankyo Inc. | $413 |
| Novartis Pharmaceuticals Corporation | $220 |
| Celgene Corporation | $179 |
| Consulting Fee | $7,048 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $3,275 |
| Food and Beverage | $2,555 |
| Honoraria | $1,110 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) TALZENNA · ONCOLOGY | $3,275 |
| EMD Serono, Inc. Oct 6, 2025 | Consulting FeeCompany’s descriptionAdvisory Board Participation (Fee For Service) | $2,820 |
| Springworks Therapeutics, Inc. May 16, 2025 | Consulting Fee OGSIVEO · DESMOID TUMORS | $2,188 |
| AstraZeneca Pharmaceuticals LP Jun 18, 2025 | Consulting Fee IMFINZI · Oncology | $1,340 |
| Deciphera Pharmaceuticals Inc. Mar 10, 2025 | Honoraria VIMSELTINIB · ONCOLOGY | $1,110 |
| Pfizer Inc. May 7, 2025 | Consulting Fee TALZENNA · ONCOLOGY | $700 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $546,276 in research payments for these studies, mostly to the institutions running them.
- A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
Merck Sharp & Dohme LLC - A phase 3 randomized openlabel study of PF06821497 mevrometostat in combination with enzalutamide compared with enzalutamide or docetaxel in participants with metastatic castration resistant prostate cancer previously…
Pfizer Inc. - A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Blad…
Merck Sharp & Dohme LLC - A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With …
Amgen Inc. - A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4)
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.